IONS Stock Heads Toward Biggest Single-Day Slump In Over 5 Years – Retail Calls It ‘Opportunity Of A Lifetime’
Ionis Pharmaceuticals (IONS) stock is facing its biggest single-day slump in over five years after a Phase 3 trial, in partnership with AstraZeneca, for treating transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) failed to meet its primary endpoint. Despite this setback, the companies plan a full data analysis and presentation in August, and retail investors are viewing the significant price drop as a buying opportunity, citing the stock as undervalued. Eplontersen, the drug in question, is already approved for a related condition in over 20 countries.
Avoiding Lag: Real-Time Signals in (IONS) Movement
This article provides real-time signal analysis for Ionis Pharmaceuticals Inc. (IONS), noting near-term strong sentiment potentially challenging persistent mid- and long-term weakness. It outlines specific institutional trading strategies, including position trading, momentum breakout, and risk hedging, with defined entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal strength, support, and resistance levels for IONS.
When Will Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Become Profitable?
This article analyzes Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) to determine its path to profitability. It will likely examine financial metrics and analyst forecasts to project when the company is expected to achieve positive earnings. The analysis will focus on key factors influencing its financial performance.
Ionis Pharmaceuticals, Inc. Revenue Breakdown – HAN:ISI
Ionis Pharmaceuticals, Inc. (ISI) generated €803.74 million in revenue last year, primarily from its RNA-targeted Medicines segment, which contributed €803.49 million. The United States was the largest geographical contributor, accounting for the entire €803.49 million of the segment's revenue. This represents an increase from the previous year's revenue of €681.15 million.
What Ionis Pharmaceuticals (IONS)'s Phase 3 Wins Mean For Shareholders
Ionis Pharmaceuticals recently announced positive Phase 3 trial results for two RNA-targeted medicines, ulefnersen and sefaxersen, showcasing the potential of its antisense platform in rare neurodegenerative and kidney diseases. These clinical successes are crucial for the R&D-heavy company, which is currently loss-making, as they could lead to future product and royalty streams and diversify pipeline risk. The focus now shifts to potential regulatory filings and how these wins will influence Ionis's path to profitability, with analysts forecasting significant revenue and earnings growth by 2029.
Operating cash flow per share of Ionis Pharmaceuticals, Inc. – HAN:ISI
This article provides financial information for Ionis Pharmaceuticals, Inc. (ISI) on the Hannover Stock Exchange, specifically focusing on its operating cash flow per share. It appears to be a data point or a financial metric overview without detailed analysis or further context.
Return on invested capital % of Ionis Pharmaceuticals, Inc. – HAN:ISI
This article focuses on the "Return on invested capital %" for Ionis Pharmaceuticals, Inc. (ISI) traded on the Hannover Stock Exchange. The content provided is minimal, indicating the market is closed with no trades, and mainly serves as a placeholder for financial data that would typically be displayed on TradingView.
Ionis Pharmaceuticals Inc. (IONS) Stock Price | Live Quotes & Charts | NASDAQ
The NASDAQ page for Ionis Pharmaceuticals Inc. (IONS) provides live quotes, charts, and basic financial information for the company. As of the data provided, IONS was trading at $45.89, up $0.32 (0.70%), with prices delayed. The page notes that there are currently no analyst ratings or earnings information available for the company.
Form 8K IONIS PHARMACEUTICALS For: 23 September By Investing.com
The article reports on an 8K filing by IONIS PHARMACEUTICALS on September 23. It provides a brief mention of the filing along with stock performance data for IONS and various financial market indices and commodities. The article mainly serves as a placeholder for the SEC filing announcement within a financial news portal.
Roche, Ionis RNA drug scores in kidney disease study
Roche and Ionis Pharmaceuticals announced that their experimental RNA drug, sefaxersen, met its primary goal in a Phase 3 clinical trial for IgA nephropathy. The drug showed significant improvements in urinary protein levels, a key indicator of kidney health. If approved, sefaxersen would compete with existing therapies like Novartis' Fabhalta, offering a once-monthly self-injection for a condition that has garnered significant attention from drugmakers.
Ionis to Seek Expedited FDA Review for ALS Drug
Ionis Pharmaceuticals and Otsuka reported positive Phase 3 FUSION trial results for ulefnersen, an investigational RNA-targeted medicine for FUS-ALS. The drug met its primary endpoint by significantly improving functional impairment and survival, and also showed positive results across key secondary endpoints and a favorable safety profile. Ionis and Otsuka plan to discuss expedited FDA submission pathways for approval, as ulefnersen is the first treatment targeting the underlying genetic cause of FUS-ALS to demonstrate potential disease modification.
Ionis reports positive Phase 3 interim results for sefaxersen in IgA nephropathy
Ionis Pharmaceuticals (IONS) announced positive prespecified interim Phase 3 results for sefaxersen in IgA nephropathy, demonstrating a statistically significant and clinically meaningful reduction in proteinuria versus placebo at 37 weeks. The study also confirmed a safety and tolerability profile consistent with previous data, with no new safety signals. Roche, which licensed sefaxersen from Ionis, will continue with the study to assess two-year eGFR change.
Ionis Phase 3 sefaxersen trial meets IgAN endpoint
Ionis Pharmaceuticals announced that its partner Roche's Phase 3 IMAgINATION trial for sefaxersen met its primary endpoint in IgA nephropathy, showing a statistically significant reduction in urine protein compared to placebo at week 37. While the interim analysis confirmed efficacy and consistent safety, key details like the magnitude of effect, p-value, and confidence interval were not disclosed. The companies plan to present the full data at a medical meeting, with the longer-term kidney function comparison remaining blinded until week 105.
Ionis drug meets primary goal in rare ALS gene mutation trial
Ionis Pharmaceuticals Inc. announced that its drug ulefnersen met its primary endpoint in a Phase 3 trial for amyotrophic lateral sclerosis (ALS) caused by mutations in the fused in sarcoma (FUS) gene. The FUSION trial demonstrated statistically significant improvement in functional impairment and survival compared to placebo. Otsuka Pharmaceutical, which licensed ulefnersen from Ionis, plans to discuss expedited submission pathways with health authorities.
Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS
Ionis Pharmaceuticals and Otsuka Pharmaceutical announced positive topline results from the Phase 3 FUSION trial of ulefnersen for FUS-ALS, a rare and aggressive form of ALS. The study met its primary endpoint, demonstrating statistically significant improvement in functional impairment and survival, positioning ulefnersen as the first potential disease-modifying treatment for FUS-ALS. The companies plan to discuss these results with regulatory authorities globally for potential expedited submission pathways and present detailed findings at upcoming medical congresses.
Ionis Pharmaceuticals Stock Plummets Yet Analysts Remain Optimistic
Ionis Pharmaceuticals (IONS) has experienced a significant stock decline of over 40% this year due to clinical trial failures, yet analysts maintain an optimistic average price target of $83.82. The company's new neurology therapy, Zanvastro, priced at $285,000 per dose, is anticipated to generate over $100 million in peak annual sales. Despite profitability being years away, Ionis possesses a strong financial position with $2.1 billion in cash and strategic partnerships to support its clinical trials and commercialization efforts.
Novartis (NVS) and Ionis (IONS)’ Big Cholesterol Bet Comes Up Short in Late-Stage Trial
Novartis and Ionis' experimental cholesterol-lowering drug, pelacarsen, failed to reduce heart attacks and strokes in a late-stage trial, despite successfully lowering Lp(a) levels. This setback impacted both companies' stock prices and removes a significant potential growth driver, increasing pressure on Novartis's remaining pipeline. While the Lp(a) market still presents an unmet need, the failure raises questions about the efficacy of deeper Lp(a) reduction in preventing cardiovascular events.
Ionis Pharmaceuticals stock hits 52-week low at $50.00
Ionis Pharmaceuticals (IONS) stock has hit a 52-week low of $50.00, marking a significant decline of 18.06% over the past year and nearly 35% year-to-date in 2026. This downturn follows disappointing trial results for its drug pelacarsen, leading multiple analyst firms to cut their price targets, despite some still seeing potential upside for the biotechnology company.
Rx Rundown: GSK, Novartis, Ionis Pharmaceuticals and more
This "Rx Rundown" article summarizes the latest medical marketing news, dealmaking, and industry chatter from September 2026. Key updates include GSK's significant upfront payment to Hutchmed, multiple FDA approvals and priority reviews for drugs from companies like Ionis Pharmaceuticals, Bayer, and AstraZeneca, and substantial funding rounds for various biotech firms. The report also highlights Novartis's recent pipeline setbacks and several industry news items such as bankruptcies, successful trial results, and new partnerships.
Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here's the Bet She's Making.
Cathie Wood's Ark Invest has recently purchased shares of Ionis Pharmaceuticals (IONS), a company specializing in RNA-targeting technologies, despite its stock being down over 28% year-to-date. This move comes after Ionis faced setbacks with two development treatments, but the company reported significant revenue growth in Q2 and is shifting towards bringing its own treatments to market. While the stock's valuation is high and the company is not yet profitable, Wood's investment signals a belief in its long-term potential, though individual investors are cautioned to conduct their own due diligence.
Raymond James cuts Ionis Pharmaceuticals price target on trial miss
Raymond James has lowered its price target for Ionis Pharmaceuticals (NASDAQ:IONS) from $87 to $84, while maintaining an Outperform rating, after the drug pelacarsen failed its primary endpoint in a Phase 3 trial. Analyst Tiago Fauth removed the drug's milestone and royalty economics from the financial model. Despite this setback, the firm's positive outlook for Ionis is bolstered by the ongoing launch of Tryngolza, and the impact of the pelacarsen trial miss is considered contained relative to the broader investment thesis.
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were down on Tuesday morning, with the Dow falling over 400 points. Several stocks, including Novartis and Ionis Pharmaceuticals, saw significant declines in pre-market trading. Novartis's shares fell after its pelacarsen phase III Lp(a) HORIZON trial did not meet its primary endpoint, impacting Ionis Pharmaceuticals due to a licensing agreement.
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander Disease - Slideshow
Ionis Pharmaceuticals, Inc. has published a slide deck discussing the FDA approval and launch strategy for their drug ZANVASTRO, intended for the treatment of Alexander Disease. This content is presented as a slideshow, providing insights into the company's plans following regulatory clearance.
Ionis Drug Wins FDA Approval as First Alexander Disease Treatment
The FDA has approved Ionis Pharmaceuticals' drug Zanvastro (zilganersen) as the first disease-modifying treatment for Alexander disease, a rare neurological disorder. The drug addresses the underlying genetic cause by reducing GFAP protein production and has shown significant improvements in motor function in clinical trials. Ionis has also partnered with Recordati for European and Japanese commercialization, with regulatory filings planned for 2027.
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
Ionis Pharmaceuticals announced that its partner Novartis' Phase 3 Lp(a)HORIZON study for pelacarsen did not meet its primary endpoint of reducing cardiovascular events, despite significantly lowering Lp(a) levels. Pelacarsen demonstrated an acceptable safety profile, and the full data will be presented at an upcoming medical congress. Ionis, which discovered pelacarsen and conducted early development before licensing it to Novartis, continues to focus on its commercialized medicines and pipeline.
Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines
A drug developed by Novartis and Ionis Pharmaceuticals, pelacarsen, failed to reduce the risk of major cardiovascular events in a large Phase 3 clinical trial, despite successfully lowering levels of lipoprotein(a) (Lp(a)). This outcome has cast doubt on an emerging class of heart medicines targeting Lp(a) and raises significant questions for other companies, such as Eli Lilly, Amgen, and Silence Therapeutics, that are developing similar therapies. The detailed trial results, expected at an upcoming medical meeting, will be crucial for understanding the implications for future cardiovascular drug development.
Ionis Pharmaceuticals Wins FDA Approval for First Alexander Disease Treatment
Ionis Pharmaceuticals received FDA approval for ZANVASTRO, the first disease-modifying treatment for Alexander disease, an ultra-rare neurological disorder. The approval, covering children and adults, was based on a trial demonstrating statistically significant stabilization of gait and improvements in motor function. Ionis plans to launch ZANVASTRO, priced at $285,000 per quarterly dose, focusing on specialized treatment centers and expects peak sales to exceed $100 million.
Ionis Pharma's drug becomes first FDA-approved treatment for rare brain disorder
The U.S. FDA has approved Ionis Pharmaceuticals' drug, Zanvastro (zilganersen), as the first treatment for Alexander disease, a rare neurological disorder. The injectable drug targets the underlying cause of the disease by blocking the production of a problematic protein, GFAP. Analysts project Zanvastro could achieve peak annual sales of $295 million.
US FDA approves Ionis Pharma’s therapy to treat rare brain disorder
The U.S. FDA has approved Ionis Pharmaceuticals' injectable drug zilganersen, branded as Zanvastro, to treat Alexander disease, a rare neurological disorder. This marks the first approved treatment for the genetic condition, which damages brain cells and affects movement, speech, and swallowing. Analysts project the drug could generate peak annual sales of $295 million.
Ionis to present at upcoming September 2026 investor conferences
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced its management will participate in fireside chats at two investor conferences in September 2026: the 21st Annual Wells Fargo Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. Live webcasts and replays of these presentations will be available on the Investors & Media section of Ionis's website. The company specializes in RNA-targeted medicines for serious diseases in neurology, cardiometabolic disease, and other high patient need areas.
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
Ionis Pharmaceuticals' partner Novartis announced that the Phase 3 Lp(a)HORIZON study for pelacarsen, designed to reduce cardiovascular events in patients with elevated lipoprotein(a) and established cardiovascular disease, did not meet its primary endpoint. Despite pelacarsen effectively lowering Lp(a) levels, this did not translate to a reduction in cardiovascular risk. Ionis stated that while the results were disappointing, they provide important clarity for future cardiovascular care.
Trading Systems Reacting to (IONS) Volatility
This article analyzes Ionis Pharmaceuticals Inc. (NASDAQ: IONS) volatility, highlighting conflicting sentiment across time horizons and a mid-channel oscillation pattern. It presents an exceptional 63.5:1 risk-reward setup targeting an 18.9% gain versus 0.3% risk. The article details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, support, and resistance levels for the stock.
H.C. Wainwright reiterates Ionis stock rating on competitive data
H.C. Wainwright maintained a Buy rating and $115 price target for Ionis Pharmaceuticals (NASDAQ:IONS), citing the competitive performance of its drug TRYNGOLZA against Arrowhead Pharmaceuticals' plozasiran in treating acute pancreatitis. While Ionis's stock is up 43% over the past year despite a 23% year-to-date decline, analysts have recently lowered earnings estimates due to its overvalued status. The firm anticipates TRYNGOLZA's launch traction in Q3 2026 as a potential catalyst, with formal payer policies expected to develop through 2027.
AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease
New study results from AstraZeneca and Ionis Pharmaceuticals have raised questions about the efficacy of RNA-based drugs like Alnylam's Amvuttra for transthyretin-mediated amyloidosis cardiomyopathy. Their drug, eplontersen, did not show a statistically significant reduction in cardiovascular events or death when added to standard therapies, surprising investors and analysts. This outcome suggests the incremental benefit of combining "silencer" medications with existing "stabilizer" drugs might be smaller than previously thought, leading to a dip in Alnylam's shares and calls for potential changes in future drug trial designs.
Why Is Ionis Pharmaceuticals (IONS) Up 17.2% Since Last Earnings Report?
Ionis Pharmaceuticals (IONS) shares have risen 17.2% since its last earnings report, outperforming the S&P 500. The company reported a narrower-than-expected Q2 2026 adjusted loss per share and revenues that beat estimates, driven by commercial growth and partnered programs. Despite a year-over-year revenue decline due to a tough comparison with a past upfront payment, the company reaffirmed its full-year 2026 revenue and operating loss guidance, with strong sales momentum for products like Dawnzera and Tryngolza.
Canaccord reiterates Ionis Pharmaceuticals stock Buy rating at $95 By Investing.com
Canaccord Genuity has reiterated its Buy rating and $95 price target for Ionis Pharmaceuticals following recent investor meetings. The firm highlighted Ionis's two approved products, Tryngolza and Dawnzera, and anticipates two potential product approvals in the coming months for Zilganersen and Bepirovirsen. Despite analysts not expecting profitability this year, Ionis reaffirmed its goal to achieve cash flow breakeven by 2028, with strong liquid assets.
FDA Expands IONS' Tryngolza Label to Treat Severe Hypertriglyceridemia
The FDA has expanded the label for Ionis Pharmaceuticals' drug, Tryngolza (olezarsen), to treat severe hypertriglyceridemia (sHTG), making it the first approved treatment for this condition in the U.S. This approval significantly broadens Tryngolza's market, as it was previously approved only for familial chylomicronemia syndrome (FCS). Ionis plans to launch the drug for sHTG next month, leveraging its first-mover advantage in a market affecting nearly 3 million people.
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) reported a Q1 loss of $0.3 per share, significantly beating the Zacks Consensus Estimate of a $0.85 loss and improving from a $0.75 loss a year ago. The company also exceeded revenue expectations, posting $246 million against an estimate of $132 million. Despite this positive earnings surprise, Ionis Pharmaceuticals' shares have declined by 9.3% year-to-date, contrasting with the S&P 500's 4.3% gain.
The Bull Case For Ionis Pharmaceuticals (IONS) Could Change Following New ESC 2026 RNA Data Package – Learn Why
Ionis Pharmaceuticals will present new data for TRYNGOLZA, early-stage results for ION775, and Phase 3 eplontersen data at the ESC Congress 2026. This data package showcases Ionis’ broad RNA medicines platform in cardiometabolic and rare diseases, potentially reinforcing confidence in revenue guidance and long-term margin leverage. However, the company remains loss-making and reliant on partner economics, with its investment narrative dependent on multiple late-stage outcomes.
Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026
Ionis Pharmaceuticals will present new data on severe hypertriglyceridemia (sHTG) at the European Society of Cardiology (ESC) Congress 2026. The presentations will include one-year data for TRYNGOLZA®, a recently approved treatment for sHTG, and Phase 1 data for ION775, an investigational siRNA. These presentations aim to highlight Ionis's continued leadership and commitment to advancing treatments for sHTG.
Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026
Ionis Pharmaceuticals will present new data on severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026. This includes one-year data for TRYNGOLZA® (olezarsen), recently approved in the U.S. for sHTG, and Phase 1 data for ION775, a next-generation investigational treatment. The presentations aim to reinforce Ionis' leadership and commitment to advancing treatments for sHTG, a condition posing a significant risk of acute pancreatitis.
IONS Looks 26.4% Overvalued on GF Value™
Ionis Pharmaceuticals (NASDAQ: IONS) is considered 26.4% overvalued according to GuruFocus's GF Value™ metric, trading at $60.80 per share against an intrinsic value of $48.09. The company's Price-to-Sales ratio of 11.38 is above its historical median, suggesting high investor expectations for future revenue growth despite its current unprofitability. Ionis holds a moderate GF Score™ of 70/100, indicating strong growth but weaknesses in profitability and financial strength, with a notable net selling trend from insiders.
Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026
Ionis Pharmaceuticals (Nasdaq: IONS) announced it will present new data on severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026. The presentations will include one-year data for TRYNGOLZA® (olezarsen), recently approved in the U.S. for sHTG, and Phase 1 data for ION775, a next-generation investigational siRNA. These presentations aim to reinforce Ionis' leadership and commitment to advancing treatments for sHTG, a condition that poses a risk of life-threatening acute pancreatitis.
Why Is Ionis Pharmaceuticals (IONS) Pushing RG-6299 Into A Pivotal Phase III Trial?
Ionis Pharmaceuticals, in collaboration with Roche and Chugai, is advancing RG-6299, an antisense therapy for IgA nephropathy, into a global Phase III trial. This move supports Ionis's strategy of leveraging late-stage RNA programs and partnerships to expand revenue and address unmet medical needs. Investors should monitor upcoming data readouts from the Phase III trial, focusing on proteinuria reduction and kidney function outcomes.
Eagle Health Investments LP Acquires New Position in Ionis Pharmaceuticals, Inc. $IONS
Eagle Health Investments LP has acquired a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), purchasing 194,577 shares valued at approximately $15.4 million, making it 2.6% of their portfolio. Despite significant insider selling totaling $18.3 million over the past 90 days, analysts maintain a "Moderate Buy" rating with a consensus price target of $94.15. The company's stock opened at $60.80, and while quarterly revenue decreased year-over-year, its adjusted loss was narrower than anticipated.
Great Lakes Advisors LLC Acquires Shares of 66,924 Ionis Pharmaceuticals, Inc. $IONS
Great Lakes Advisors LLC has acquired 66,924 shares of Ionis Pharmaceuticals (NASDAQ:IONS) in the second quarter, valued at approximately $5.3 million. This comes as institutional investors and hedge funds own 93.86% of IONS, despite company insiders selling over $18 million worth of shares. Ionis Pharmaceuticals reported strong quarterly revenue of $267.95 million, beating analyst estimates, but its revenue was down 40.7% year-over-year.
Edmond DE Rothschild Holding S.A. Makes New Investment in Ionis Pharmaceuticals, Inc. $IONS
Edmond DE Rothschild Holding S.A. has acquired a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), purchasing 113,320 shares valued at approximately $8,985,000 during the second quarter. This move comes as other institutional investors have also adjusted their positions in the company, and insiders have recently sold significant amounts of stock. Analysts currently hold a "Moderate Buy" consensus rating for Ionis Pharmaceuticals with a target price of $94.15.
Why Is Ionis Pharmaceuticals (IONS) Pushing RG-6299 Into A Pivotal Phase III Trial?
Ionis Pharmaceuticals, in collaboration with Roche and Chugai, is advancing RG-6299, an antisense therapy for IgA nephropathy, into a global Phase III trial. This move targets an unmet medical need and aligns with Ionis' strategy of leveraging its RNA platform through partnerships for late-stage drug development. Successful trial results could lead to regulatory filings and commercialization, reinforcing Ionis' revenue and margin growth narrative.
TimesSquare Capital Management LLC Takes $48.69 Million Position in Ionis Pharmaceuticals, Inc. $IONS
TimesSquare Capital Management LLC has acquired a new position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), purchasing 614,070 shares valued at $48.69 million, making it a 0.37% owner of the company. Other institutional investors also adjusted their holdings in Ionis, which saw its stock open at $58.63 with a market cap of $9.74 billion. Despite a consensus "Moderate Buy" rating from analysts with an average price target of $94.65, the company reported a year-over-year revenue decline of 40.7% and remains unprofitable, though it beat quarterly earnings estimates.
Grandfield & Dodd LLC Invests $2.94 Million in Ionis Pharmaceuticals, Inc. $IONS
Grandfield & Dodd LLC recently invested $2.94 million in Ionis Pharmaceuticals, acquiring 37,077 shares. Institutional investors collectively own a significant 93.86% of the company, and analysts maintain a "Moderate Buy" rating despite some recent target reductions. The company surpassed Q2 revenue and EPS expectations, though insiders have sold a notable amount of stock recently.
